- Active, not recruiting
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
Updated: Feb 4
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
Modakafusp alfa (Formerly TAK-573)
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
The main aims of this study is to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Participants will be given modakafusp alfa through a vein.
Sponsor:
ClinicalTrials.gov Identifier: NCT05556616
Official Title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma
First Posted : September 27, 2022
Click here to see details on ClinicalTrials.gov
Drug: Modakafusp alfa
Drug: Lenalidomide
Drug: Bortezomib
Drug: Carfilzomib
Drug: Daratumumab
Drug: Pomalidomide
Modakafusp Alfa (Code C140427)
Anti-CD38-targeted IgG4-attenuated IFNa TAK-573
Anti-CD38-targeted IgG4-attenuated Interferon Alpha TAK-573
CD38-targeted IgG4 Fused with Attenuated IFNa
Modakafusp Alfa
MODAKAFUSP ALFA
TAK-573
Locations
United States, Arkansas
United States, California
United States, Colorado
United States, Florida
United States, Iowa
United States, Kansas
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, Nevada
United States, New York
United States, North Carolina
United States, Ohio
United States, Pennsylvania
United States, Tennessee
United States, Texas
Canada, Ontario
Canada, Quebec
Europe
Asia
Austria
Belgium
Israel
Italy
Spain
United Kingdom